Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis.
Orforglipron may lead to significant weight loss and improvements in glycemic control, but gastrointestinal side effects may increase with higher doses.
Where it sits
this study against the rest of the orforglipron (ly-3502970) corpusSummary and findings
This meta-analysis evaluated the efficacy and safety of once-daily oral orforglipron in obese adults with and without diabetes. The study included five randomized controlled trials with a total of 6140 participants. Results indicated weight reductions of over 6 kg at 36 mg in patients with diabetes and approaching 12 kg in those without diabetes.
Abstract
Excess body weight and poor metabolic control remain major contributors to cardiometabolic disease, highlighting the need for effective therapeutic options. This meta-analysis aimed to evaluate the efficacy and safety of once-daily oral orforglipron in obese adults with and without diabetes. Searches were conducted across four databases through November 2025. Five randomized controlled trials (n = 6140) were included. Orforglipron produced consistent, dose-dependent reductions in body weight, ranging from modest losses at 3 mg to more than 6 kg at 36 mg in patients with diabetes. Individuals without diabetes experienced greater weight reductions, approaching 12 kg at the highest dose. Significant improvements in body mass index, waist circumference, and glycated hemoglobin (HbA1c; -1.29%) were also observed. Gastrointestinal adverse events increased with higher dose, and no significant difference in the incidence of acute pancreatitis was identified. Overall, orforglipron demonstrated clinically meaningful metabolic benefits with an acceptable safety profile.
Background
This paper addresses the ongoing challenge of managing excess body weight and poor metabolic control, which are significant contributors to cardiometabolic disease. Prior research has established the role of GLP-1 receptor agonists in weight management; however, the specific efficacy of oral formulations like orforglipron in diverse populations remains less understood. This study is significant as it aggregates data from multiple trials to provide a clearer picture of orforglipron's potential benefits and risks.
Methods
The study is a systematic review and meta-analysis that included five randomized controlled trials with a total sample size of 6140 participants. The trials evaluated the effects of once-daily oral orforglipron at various doses, with a focus on weight loss and glycemic control. Specific dose information and duration of treatment were not reported in the abstract.
Results
The primary endpoint indicated a reduction in HbA1c of -1.29%, n=6140. Additionally, weight loss was reported as more than 6 kg at the 36 mg dose for patients with diabetes and approaching 12 kg for those without diabetes. The analysis also noted an increase in gastrointestinal adverse events with higher doses, although no significant difference in acute pancreatitis incidence was found.
Interpretation
These findings suggest that orforglipron may provide meaningful metabolic benefits, particularly in weight loss among obese individuals. However, while the statistical significance of the results is noted, the clinical significance, particularly in terms of weight loss and HbA1c reduction, should be interpreted with caution given the variability in individual responses and potential confounding factors such as trial design and participant characteristics. The increase in gastrointestinal events with higher doses also raises concerns about tolerability.
Key findings
- Weight loss of more than 6 kg at 36 mg in patients with diabetes, n=6140.
- Weight loss approaching 12 kg at the highest dose in individuals without diabetes, n=6140.
- Reduction in HbA1c of -1.29%, n=6140.
- Gastrointestinal adverse events increased with higher doses, n=6140.
- No significant difference in the incidence of acute pancreatitis, n=6140.
Limitations
- Meta-analysis of five trials, potential variability in study designs.
- Specific dosing regimens and follow-up duration not detailed.
- No long-term data on durability of effects.
- Potential publication bias in included studies.